| Literature DB >> 36004222 |
Eiri Kisamori1, Yasuhiro Kotani1, Fiza Komel Raja1, Junko Kobayashi1, Yosuke Kuroko1, Takuya Kawabata1, Shingo Kasahara1.
Abstract
Objective: Repair of total anomalous pulmonary venous connection (TAPVC) in neonates with right atrial isomerism and functional single ventricle is challenging. In our novel strategy, primary draining vein stenting (DVS) was applied to patients with preoperative pulmonary vein obstruction to delay TAPVC repair. This study investigated our initial experience with a strategy of delayed TAPVC repair, incorporating DVS.Entities:
Keywords: DVS, draining vein stenting; PVO, pulmonary vein obstruction; TAPVC, total anomalous pulmonary venous connection; congenital heart disease; neonate; right isomerism; stent implantation; surgical repair; total anomalous pulmonary venous connection
Year: 2022 PMID: 36004222 PMCID: PMC9390631 DOI: 10.1016/j.xjon.2021.11.012
Source DB: PubMed Journal: JTCVS Open ISSN: 2666-2736
Figure 1Of the 50 patients who underwent surgical repair of total anomalous pulmonary venous connection (TAPVC) with right atrial isomerism and functional single ventricle, 29 consecutive patients had a severe obstruction in the course of draining veins and needed surgical or catheter intervention in their neonatal periods. These cases were divided into those who underwent primary draining vein stenting (n = 11) or primary TAPVC repair (n = 18). Kaplan–Meier analysis showed a better survival in the primary draining vein stenting group compared with the primary TAPVC repair (P = .045).
Type of stent used for primary draining vein stenting
| Patient | Stent type | Stent diameter (mm) |
|---|---|---|
| 1 | Palmaz Genesis | 5 × 15 |
| 2 | Palmaz Genesis | 6 × 15 |
| 3 | BMX | 3.5 × 24 |
| 4 | Palmaz Genesis | 6 × 10 |
| 5 | Resolute Onyx | 4 × 22 |
| 6 | Resolute Integrity | 3.5 × 30 |
| 7 | Omnilink Elite | 7 × 19 |
| 8 | BMX | 3.5 × 18 |
| 9 | Nobori | 3.5 × 18 |
| 10 | Nobori | 3.5 × 24 |
| 11 | Genesis | 5 × 18 |
Palmaz Genesis are from Cardinal Health, BMX from Biosensors, Resolute Onyx and Resolute Integrity are from Medtronic, Omnilink Elite from Abbott, and Nobori is from Terumo. BMX, BioMatrix.
Patient characteristics
| Variable | Primary draining vein stenting (n = 11) | Primary TAPVC repair (n = 18) | |
|---|---|---|---|
| Female sex | 5 (45.5) | 10 (55.6) | .60 |
| Birth weight (IQR), kg | 2.6 (2.3-3.0) | 2.7 (2.6-3.1) | .31 |
| TAPVC | |||
| Supracardiac type | 3 (27.3) | 10 (55.6) | .14 |
| Infracardiac type | 3 (27.3) | 6 (33.3) | .73 |
| Mixed type | 5 (45.5) | 2 (11.1) | .03 |
| Sutureless technique | 2 (18.2) | 0 (0) | .06 |
| Functional single ventricle with common atrioventricular valve | .08 | ||
| Unbalanced atrioventricular septal defect | 10 (90.9) | 11 (61.1) | |
| Common inlet right ventricle | 1 (9.1) | 7 (38.9) | |
| Common inlet left ventricle | 0 | 0 | |
| Pulmonary valve | .10 | ||
| Stenosis | 9 (81.8) | 8 (44.5) | |
| Atresia | 2 (18.2) | 6 (33.3) | |
| Major aortopulmonary collateral artery | 1 (9.1) | 0 | .19 |
| Systemic venous drainage | .06 | ||
| Bilateral superior vena cava | 6 (54.6) | 4 (22.2) | |
| Left-sided superior vena cava | 2 (18.2) | 1 (5.6) | |
| Moderate or severe common atrioventricular valve regurgitation | 4 (36.4) | 2 (16.7) | .28 |
| Systemic to pulmonary shunt | 9 (81.8) | 6 (33.3) | .04 |
| Emergent intervention (within 24 h of birth) | 2 (18.1) | 8 (44.4) | .14 |
Data are presented as n (%) except where otherwise noted. TAPVC, Total anomalous pulmonary venous connection; IQR, interquartile range.
Clinical courses
| Primary draining vein stenting (n = 11) | Primary TAPVC repair (n = 18) | ||
|---|---|---|---|
| Follow-up period, months | 33.4 (9.3-62.7) | 4.3 (1.7-103) | .28 |
| Primary draining stenting age, days | 8 (4-16) | – | |
| Stenting site | |||
| Vertical vein | 7 | – | |
| Ductus venosus | 4 | – | |
| TAPVC repair age, days | 88 (58-106) | 8.5 (0-18) | <.01 |
| Postoperative PVO | 5 (45.5) | 6 (46.2) | .97 |
| Reintervention for PVO | 5 (45.5) | 3 (16.7) | .09 |
| Patients who reached or waiting for Glenn operation | 8 (72.7) | 9 (50) | .28 |
| Fontan completion or awaiting Fontan operation | 5 (45.5) | 6 (33.3) | .38 |
Data are presented as median (interquartile range) or n (%) except where otherwise noted. TAPVC, Total anomalous pulmonary venous connection; PVO, pulmonary vein obstruction.
Details of each patient
| Patient | TAPVC type | Cardiac anatomy | Surgery before TAPVC repair | Concomitant procedures | Subsequent procedures | Age | Cause of death |
|---|---|---|---|---|---|---|---|
| Primary draining vein stenting | |||||||
| 1 | Mixed | SV, CAVV, PA, LSVC | m-BTS | LOS | |||
| 2 | Supracardiac | DORV, Hypoplastic LV, CAVV, PS, MAPCA, Rt AoA | m-BTS | PVO release Unifocalization | 8 Months | Respiratory failure | |
| 3 | Infracardiac | SV, CAVV, PS, Bil. SVC, Rt AoA, PDA | m-BTS | CAVV repair | 7 Months | Heart failure | |
| CAVV replacement | 1 Year | ||||||
| PM implantation | 1 Year | ||||||
| 4 | Supracardiac | SV, CAVV, PS | m-BTS | BDG | 10 Months | TCPC graft embolism | |
| TCPC | 1 Year | ||||||
| 5 | Mixed | SV, CAVV, PS | CAVV repair | m-BTS | 28 Days | ||
| 6 | Infracardiac | SV, PA, PDA, Rt AoA, Bil. SVC | PDA banding | ||||
| 7 | Supracardiac | SV, CAVV, PS, Bil. SVC, Rt AoA, PDA | Pulmonary artery banding | BDG | 6 Months | ||
| CAVV repair | 1 Year | ||||||
| 8 | Mixed | SV, CAVV, PS, Bil. SVC, Rt AoA | Main pulmonary artery banding | BDG and PVO release (open stent) | 6 Months | ||
| 9 | Mixed | SV, CAVV, PS | CAVV repair | PVO release | 6 Months | ||
| PVO release | 1 Year | ||||||
| PVO release (open stent) | 1 Year | ||||||
| BDG | 1 Year | ||||||
| CAVV replacement | 3 Years | ||||||
| Glenn take down | 5 Years | ||||||
| 10 | Infracardiac | SV, CAVV, PS, Bil. SVC | m-BTS | BDG and Pulmonary artery banding | PVO release | 7 Months | |
| PVO release | 10 Months | ||||||
| PVO release | 1 Year | ||||||
| PVO release (open stent) | 1 Year | ||||||
| 11 | Mixed | SV, CAVV, PA, LSVC | m-BTS, Draining vein repair | ASD enlargement | BDG | 1 Year | |
| TCPC | 3 Years | ||||||
| Primary TAPVC repair | |||||||
| 1 | Infracardiac | SV, CAVV, PS | LOS | ||||
| 2 | Supracardiac | SV, CAVV, PA | m-BTS | LOS | |||
| 3 | Mixed | SRV, PA | m-BTS | LOS | |||
| 4 | Infracardiac | SRV, CAVV, PA | RV-pulmonary artery shunt | Heart failure | |||
| 5 | Infracardiac | SRV, CAVV, PS | Sepsis | ||||
| 6 | Supracardiac | SRV, CAVV | Respiratory failure | ||||
| 7 | Supracardiac | SV, CAVV, PS | pulmonary artery banding | Respiratory failure | |||
| 8 | Supracardiac | SV, CAVV, PS, Bil. SVC | Respiratory failure | ||||
| 9 | Infracardiac | DORV, CAVV, PA | RV-pulmonary artery shunt | PVO release | 2 Months | PVO | |
| 10 | Infracardiac | SV, CAVV, PA, Bil. SVC | m-BTS | BDG | 4 Months | Arrhythmia | |
| 11 | Supracardiac | SV, CAVV, PS | BDG | 7 Months | Respiratory failure | ||
| Glenn take down | 8 Months | ||||||
| 12 | Mixed | SV, CAVV, PS, LSVC | BDG | 9 Months | |||
| PM implantation | 9 Months | ||||||
| Glenn take down | 1 Year | ||||||
| 13 | Supracardiac | SRV, CAVV, PA | RV-pulmonary artery shunt | BDG | 7 Months | ||
| TCPC | 2 Years | ||||||
| PVO release | 6 Years | ||||||
| 14 | Supracardiac | SV, CAVV, PS, Bil. SVC | BDG | 4 Months | |||
| TCPC | 2 Years | ||||||
| PM implantation | 2 Years | ||||||
| 15 | Supracardiac | SV, CAVV, Bil. SVC, Rt AoA | pulmonary artery banding | Bilateral BDG | 1 Year | ||
| TCPC | 2 Years | ||||||
| 16 | Supracardiac | SRV, CAVV, DORV, PS, Bil. SVC | pulmonary artery banding | PVO release | 3 Months | ||
| BDG | 6 Months | ||||||
| TCPC | 3 Years | ||||||
| 17 | Infracardiac | SV, CAVV | pulmonary artery banding | BDG | 1 Year | ||
| TCPC | 2 Years | ||||||
| 18 | Supracardiac | DORV, CAVV | Pulmonary artery banding | BDG | 7 Months | ||
TAPVC, Total anomalous pulmonary venous connection; SV, functional single ventricle; CAVV, common atrioventricular valve; PA, pulmonary atresia; LSVC, left superior vena cava; m-BTS, modified Blalock–Taussig shunt; LOS, low output syndrome; DORV, double outlet right ventricle; LV, left ventricle; PS, pulmonary stenosis; MAPCA, major aortopulmonary collateral artery; Rt AoA, right aortic arch; PVO, pulmonary venous obstruction; Bil. SVC, bilateral superior vena cava; PDA, patent ductus foramen; PM, pacemaker; BDG, bidirectional Glenn procedure; BTS, Blalock–Taussig shunt; TCPC, total cavopulmonary connection; CRT, cardiac resynchronization therapy; ASD, atrial septal defect; SRV, single right ventricle; RV, right ventricle.
Figure 2Timing of surgeries and interventions focused on pulmonary venous obstruction. Primary total anomalous pulmonary venous connection repair was performed immediately after birth, whereas primary draining venous stenting delayed total anomalous pulmonary venous connection repair were done beyond the neonatal period. The overall mortality was 36.4% in the primary draining venous stenting group versus 61.1% in the primary total anomalous pulmonary venous connection repair group. Nine of 11 deaths in the primary total anomalous pulmonary venous connection group were observed before Glenn procedure.
Pulmonary venous obstruction
| Patient | TAPVC type | Postoperative PVO gradient (catheter), mm Hg | Postoperative peak velocity (echo) m/sec | Intervention | Stenotic site | Nonconfluent PV |
|---|---|---|---|---|---|---|
| Primary draining vein stenting | ||||||
| 2 | Supracardiac | 1.4 | Stent | Multivessel | + | |
| 7 | Supracardiac | 3 | 1.5 | Surgical PVO release | Single vessel | − |
| 8 | Mixed | 1.2 | Surgical PVO release | Multivessel | + | |
| 9 | Mixed | 10 | 2.1 | Surgical PVO release | Multivessel | − |
| 10 | Infracardiac | 5 | 2 | Surgical PVO release | Multivessel | + |
| Primary TAPVC repair | ||||||
| 8 | Supracardiac | 1.3 | Anastomosis site | − | ||
| 9 | Infracardiac | 1.3 | Surgical PVO release | Multivessel | + | |
| 12 | Mixed | 1.2 | Anastomosis site | − | ||
| 13 | Supracardiac | 1.4 | Surgical PVO release | Multivessel | − | |
| 16 | Supracardiac | 2.5 | Surgical PVO release | Multivessel | − | |
| 18 | Supracardiac | 1.4 | Anastomosis site | − | ||
TAPVC, Total anomalous pulmonary venous connection; PVO, pulmonary venous connection; PV, pulmonary vein; BAP, balloon angioplasty; +, nonconfluent pulmonary vein; −, confluent pulmonary vein.
Figure 3Kaplan–Meier analysis of overall survival for each group. Kaplan–Meier analysis showed that primary draining venous stenting repair was associated with improved survival compared with primary total anomalous pulmonary venous connection repair (survival rates at 90 days, 1 year, 3 years, and 5 years): primary draining venous stenting: 100%, 80%, 68.6%, and 54.9%, respectively; and primary total anomalous pulmonary venous connection repair: 55.6%, 38.9%, 38.9%, and 38.9%, respectively (95% CI, 0.26-0.63; P = .045). CI, Confidence interval.
Figure 4Diagram of postsurgical outcome. All 11 patients with primary draining venous stenting underwent total anomalous pulmonary venous connection (TAPVC) repair later at a median age of 88 days. Five patients (45.5%) achieved Fontan completion or awaiting Fontan operation in the primary draining venous stenting group, whereas 6 patients (33.3%) achieved Fontan operation in the primary TAPVC group. BDG, Bidirectional Glenn procedure.
Figure 5Contrast enhanced computed tomography images of patients with ductus venous stenting. Three of the 4 patients who underwent stenting of the ductus venosus had elevated aspartate transaminase and alanine transaminase levels after total anomalous pulmonary venous connection repair. The cause of liver damage after total anomalous pulmonary venous connection repair is a result of increased blood flow from the portal vein to the ductus venosus due to decreased blood flow from the pulmonary vein to the ductus venosus. Increased shunt across the ductus venosus decreased blood flow to liver, resulting in liver damage. The elevated aspartate transaminase and alanine transaminase levels became normal soon after stent embolization.